Allergic Rhinitis Combination Pharmacotherapy Efficacy Study

• Status: Not yet recruiting
• Trial end date: 2021-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Combination pharmacotherapy is often used in people who have failed mono-therapies in managing their bothersome allergic rhinitis symptoms . However, there is a paucity of research indicating the most effective combination therapies in managing allergic rhinitis. This study aims to evaluate the efficacy of oral antihistamine (rupatadine) combined with nasal steroid (fluticasone propionate) compared to a well-studied combination therapy of nasal steroid with nasal antihistamine spray (MP-AzeFlu).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: St. Paul's Sinus Centre
• Treatments: Azelastine; Fluticasone; Xhance

Criteria

Inclusion Criteria:

1. Patient over the age of 18

2. Positive allergy skin prick test that diagnose AR

3. Persistent and Moderate-to-Severe AR (Persistent symptoms for more than 6 weeks and suffers from abnormal sleep, impairment of daily activities, work-school problems, or has troublesome symptoms; TNSS of at least 8/12)

4. Negative CT sinus

Exclusion Criteria:

1. Non-Allergic Rhinitis patients will be excluded from this study.

2. Participants who are pregnant or lactating

3. Hypersensitivity to FP, MP-AzeFlu, or Rupatadine

4. Superficial or moderate nasal erosion, nasal mucosal ulceration or nasal septum perforation, who had nasal surgery within the last year, had significant pulmonary disease (excluding intermittent asthma)

5. Participants who had inferior turbinate reduction surgery

6. Participants who smoke

7. Not able to read and understand the consent form

8. Patients suffering from nonallergic rhinitis (eg. vasomotor, infectious, or drug-induced rhinitis) or with a negative skin prick test will not be included